Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The antigen presentation via major histocompatibility complex class I pathway is central for immune surveillance against intracellular infections and malignancies. It involves proteasomal degradation of endogenous proteins into peptides that are loaded onto newly formed MHC-I complexes within the ER before being presented at the cell surface for recognition primarily by CD8+ cytotoxic T lymphocytes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antigen presentation via major histocompatibility complex class I pathway (MHC class I pathway).